Stryker Corporation announced an increase in the size of its Board of Directors to nine and the election of Dr. Roch Doliveux as a director.
Dr. Doliveux has served since 2005 as Chief Executive Officer and Chairman of the Executive Committee of UCB S.A., a global biopharmaceutical company.
Dr. Doliveux has previously been a Chief Executive Officer of Pierre Fabre Pharmaceuticals and President, Schering-Plough International, a subsidiary of Schering-Plough Corporation.
Dr. Doliveux holds a master’s degree in business from INSEAD, Fontainebleau, France. He also holds a Ph.D. in Veterinary Medicine from Maisons-Alfort, France.
Stephen P. MacMillan, Chairman, President and Chief Executive Officer of Stryker Corporation, said, “Roch brings an outstanding combination of talents and experiences as a globally-minded healthcare executive with a strong focus on patients and innovation.”
Stryker is one of the world’s leading medical technology companies and is dedicated to helping healthcare professionals perform their jobs more efficiently while enhancing patient care.
The Company provides innovative orthopaedic implants as well as state-of-the-art medical and surgical equipment to help people lead more active and more satisfying lives.
For more information about Stryker, please visit: